Global Autism Spectrum Disorder Market Overview:
Autism Spectrum Disorder (ASD) refers to the mental imbalance which is generally linked to the seizures, lack of sound sleep, and gastrointestinal (GI) distress. The heady lifestyle is the root cause of ASD's existence that is affecting a number of children as well as adults. Although many experts assert that there is no cure of Autism; following the line of treatments continually assures good outcomes. Specialists are increasingly developing breakthrough therapies and treatments using the technological advancements which are phenomenally close. Some of the key players profiled in the study are Pfizer Inc. (United States), GlaxoSmithKline plc (United Kingdom), Eli Lilly & Company (United States), Merck & CO Inc. (United States), Allergan (Ireland), Consern Pharma Pvt.Ltd. (India), Johnson & Johnson (United States) and Roche (Switzerland).
On the basis of geography, the market of Autism Spectrum Disorder has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2018. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by Indication, the sub-segment i.e. Insomnia will boost the Autism Spectrum Disorder market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Channel, the sub-segment i.e. Hospital Pharmacies will boost the Autism Spectrum Disorder market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Prevalence of Mental Disorders like Autism due to Fast life and Various Prevailing Addictions
- Rise in Demand for Sophisticated Therapy by Physicians and Patients
- Technological Advancements in the Field of Medical Science
- Lack of Awareness About Autism Spectrum Disorder in Developing Regions
- High Cost of Therapy
- Lack of Medical Infrastructure
- Collaboration & Tie ups of Leading Players
- Lack of Trained Professionals
In December 2018, Q BioMed Inc. (US), a biomedical acceleration and development company announced its partnership with SRI International (US), an independent, non-profit research centre that serves government and industry to help commercialize products to Develop Pediatric Developmental Nonverbal Disorder Therapy.
According to the CDC (Centers for Disease Control and Prevention), 1 in 68 children in the U.S is affected with an autism spectrum disorder, and each year around 50,000 children lose their basic education as they are affected with an autism spectrum disorder. Autism spectrum disorder is more shown by boys then that of girls, as per CDC itís about 4.5 more in boys than girls.
Major Objectives Focused through this Study To define, describe, and forecast the Global Autism Spectrum Disorder market on the basis of product [Applied Behavior Analysis, Discrete Trial Teaching and Pivotal Response Treatment] , application , key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Autism Spectrum Disorder market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Autism Spectrum Disorder industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Available Customization: Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Otsuka and AstraZeneca.
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Autism Spectrum Disorder market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.